Skip to main content
. 2022 Nov 23;9:1041044. doi: 10.3389/fcvm.2022.1041044

Table 2.

Meta-Analysis and TSA results of dorzagliatin for AEs.

Outcome Dorzagliatin arm
(events/total)
Placebo arm
(events/total)
I2 RR (95% CI) TSA Quality of evidence
Total AEs 59/743 37/590 0 1.56 (1.06, 2.30) No Moderate
Serious AEs 0/692 1/537 0 0.17 (0.01, 4.03) No Moderate
Hyperlipidemia 3/692 1/537 0 1.80 (0.27, 12.18) No Moderate
Hypoglycaemia 5/743 0/590 0 3.64 (0.65, 20.37) No Moderate